Morocco,
December 2023
Morocco, and its healthcare sector, have reached a pivotal moment. The North African nation is currently implementing the most ambitious, far-reaching, and comprehensive health system reorganization in its history along with a major shake-up of the regulatory frameworks governing the country’s local pharmaceuticals industry. All of this is occurring within the context of a cross-industry national strategy aimed at achieving “sovereignty” for Morocco, including for medicines and vaccines, and reducing its dependence on imports.
While such a dramatic reform programme is inevitably throwing up challenges, there are also significant opportunities for enterprising local and international actors to contribute to it. There are hopes that healthcare generalisation will further bolster the Moroccan domestic pharma market, Africa’s fourth largest and already growing at a rate of around 5.4 percent. Moreover, the country’s dense network of well-established local pharma manufacturers is increasingly setting their sights on establishing a broader global footprint.
Most eye-catchingly, the country is attempting to scale the value chain and localise large-scale vaccine manufacturing operations; building on its positioning as a life science leader and pioneer within Africa and the global south.
This report tells the story of Moroccan healthcare and life sciences in 2023 through the insights of government officials, local pharma champions, innovation-based multinationals, healthcare professionals, and service providers implanted in the country. Through these insights a picture emerges of a nation with a strengthened position in global and regional supply chains, better able to care for its own population than ever before, and with a great deal of optimism for the future.
Morocco, and its healthcare sector, have reached a pivotal moment. The North African nation is currently implementing the most ambitious, far-reaching, and comprehensive health system reorganization in its history along with a major shake-up of the regulatory frameworks governing the country’s local pharmaceuticals industry. All of this is occurring within the context of a cross-industry national strategy aimed at achieving “sovereignty” for Morocco, including for medicines and vaccines, and reducing its dependence on imports.
While such a dramatic reform programme is inevitably throwing up challenges, there are also significant opportunities for enterprising local and international actors to contribute to it. There are hopes that healthcare generalisation will further bolster the Moroccan domestic pharma market, Africa’s fourth largest and already growing at a rate of around 5.4 percent. Moreover, the country’s dense network of well-established local pharma manufacturers is increasingly setting their sights on establishing a broader global footprint.
Most eye-catchingly, the country is attempting to scale the value chain and localise large-scale vaccine manufacturing operations; building on its positioning as a life science leader and pioneer within Africa and the global south.
This report tells the story of Moroccan healthcare and life sciences in 2023 through the insights of government officials, local pharma champions, innovation-based multinationals, healthcare professionals, and service providers implanted in the country. Through these insights a picture emerges of a nation with a strengthened position in global and regional supply chains, better able to care for its own population than ever before, and with a great deal of optimism for the future.
See more
